Related Experiment Video
Updated: Mar 1, 2026
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
Silencing the Mutant KCNH2 Allele to Reduce the Effects of Long QT Syndrome Type 2
1Department of Medical Biology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Background:
Long-QT syndrome type 2 (LQTS2), which is associated with life-threatening cardiac arrhythmias, is caused by pathogenic heterozygous loss-of-function mutations in the KCNH2 gene. This gene encodes the pore-forming Kv11.1 α-subunit of the ion channel that carries the rapid delayed rectifier potassium current (IKr). Pathogenic loss-of-function mutations reduce the amplitude of IKr, thereby prolonging the action potential (AP) of ventricular cardiomyocytes, and in turn, the QT interval of the electrocardiogram (ECG). The aim of the present in silico study was to test the extent to which allele-specific suppression ('silencing') of the mutant KCNH2 allele can alleviate the effects of dominant-negative LQTS2 mutations.
Methods:
Two recent and comprehensive models of the electrical activity of a single human ventricular cardiomyocyte, i.e., the 'Bartolucci-Passini-Severi model as published in 2020' and the 'Tomek-Rodriguez model following the O'Hara-Rudy dynamic (ORd) model' (known as the BPS2020 and ToR-ORd models, respectively) were used to assess the effects of mild and severe LQTS2 mutations on the AP duration at 90% repolarization (APD90) and the APD90 restitution obtained with an S1-S2 pacing protocol.
Results:
For severe mutations, the mutation-induced prolongation of the APD90 at a stimulation rate of 1 Hz is reduced from 166% to 99% in the BPS2020 model and from 111% to 71% in the ToR-ORd model upon 70% suppression of the mutant allele. For mild mutations, this prolongation is reduced from 77% to 44% and from 57% to 34%, respectively. An even greater effect is observed when the mutant KCNH2 allele is inhibited by up to 90%, but the greater suppression is only marginal for mild mutations. The steepness of the mutant APD90 restitution curves is considerably reduced upon suppression, which may exert an anti-arrhythmic effect.
Conclusions:
Silencing of the mutant allele can substantially, but only partially, counteract the effects of mild or severe LQTS2 mutations on IKr. Allele-specific inhibition of the mutant KCNH2 allele alone is not sufficient to fully treat the effects of LQTS2 mutations and should be accompanied by a replacement gene therapy, creating a suppression-and-replacement ("SupRep") gene therapy.
Insights
Silencing the faulty KCNH2 gene in Long-QT syndrome type 2 (LQTS2) partially corrects cardiac arrhythmias. However, this approach alone is insufficient for full treatment, suggesting a combined gene therapy is needed.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Computational Biology
Background:
- Long-QT syndrome type 2 (LQTS2) arises from loss-of-function mutations in the KCNH2 gene, impairing the cardiac potassium channel (IKr).
- This impairment prolongs cardiomyocyte action potentials and the ECG QT interval, increasing arrhythmia risk.
- Current research explores *in silico* strategies to mitigate LQTS2 effects.
Purpose of the Study:
- To evaluate the efficacy of allele-specific silencing of mutant KCNH2 in counteracting LQTS2-associated APD90 prolongation.
- To assess the impact of varying suppression levels on cardiac electrophysiology models.
- To determine if KCNH2 allele silencing alone is sufficient for LQTS2 treatment.
Main Methods:
- Utilized two detailed human ventricular cardiomyocyte models: Bartolucci-Passini-Severi (BPS2020) and Tomek-Rodriguez (ToR-ORd).
- Simulated mild and severe LQTS2 mutations and assessed effects on action potential duration at 90% repolarization (APD90).
- Investigated the impact of 70% and 90% suppression of the mutant KCNH2 allele on APD90 and restitution properties.
Main Results:
- Severe LQTS2 mutation effects on APD90 were reduced by 70% allele suppression (e.g., from 166% to 99% in BPS2020).
- Mild mutation effects were also significantly reduced, though higher suppression levels yielded diminishing returns.
- Suppression of the mutant allele reduced the steepness of APD90 restitution curves, potentially offering anti-arrhythmic benefits.
Conclusions:
- Allele-specific KCNH2 silencing substantially mitigates LQTS2 effects but does not fully restore normal electrophysiology.
- A combined 'SupRep' (suppression-and-replacement) gene therapy approach is proposed for comprehensive LQTS2 treatment.
- Further research into combination therapies is warranted for effective LQTS2 management.
